Some cookies are essential to the running of the website, while others (analytics) help us to make improvements. We also incorporate functionality from other websites, such as video, social media feeds and ReachDeck (text-to-speech and translations services) which may set cookies. More on how we use cookies
This website uses text-to-speech software called ReachDeck to read and / or translate its content. To use ReachDeck, you must allow ReachDeck cookies; the ReachDeck icon will then appear at the bottom right of your screen.
You can find out more about how ReachDeck uses cookies or change your cookie preferences at any time by going to our cookies page.
Allow ReachDeck cookies Do not use ReachDeck
Please find service updates and current visiting rules in our COVID-19 section.
This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.
The direction of research is often set by researchers or by the drug industry. We want to enable patients, carers, family members, and the health and social care professionals who look after those with rare bone conditions to have their say, so that future research is aligned with what matters to everyone whose life is affected.
The JLA process brings patients, carers, family members and health and social care professionals together on an equal footing in a Priority Setting Partnership to:
Our Project Protocol document sets out the aims, objectives and commitments of the Musculoskeletal Rare Diseases in Adulthood PSP. It sets out how the project meets the principles established by the JLA. Our JLA advisor has played a central role in helping the Steering Group establish this protocol and works to ensure that accountability and transparency are maintained throughout the project.